Akoya Biosciences expands with new high-plex neurobiology panels, enhancing spatial proteomics for research in oncology and neuroscience.
Quiver AI Summary
Akoya Biosciences announced a significant expansion of its product offerings with the introduction of new high-plex neurobiology panels for human and mouse applications, enhancing their recent Human IO60 and Mouse FFPE IO panels. These new ultrahigh-plex panels aim to advance research in various fields, including oncology and neurobiology, providing deep insights into neurodegenerative diseases and therapeutic targets. The PhenoCode™ Discovery IO60 panel has already been recognized for its transformative impact on spatial proteomics, and early adopters have praised its ability to reveal complex immune interactions. The new neurobiology panels will be launched in 2025, are designed for seamless integration with the PhenoCycler®-Fusion platform, and are expected to facilitate important discoveries in neuroscience. Akoya's CEO highlighted the company's commitment to innovation and growing market presence through these new products.
Potential Positives
- Rapid menu expansion with new high-plex neurobiology panels enhances Akoya Biosciences' product portfolio and solidifies its leadership position in spatial biology.
- The introduction of ultrahigh-plex neurobiology panels addresses critical needs in neuroscience research, potentially leading to advancements in understanding neurodegenerative diseases and therapeutic development.
- Strategic alliances with leading contract research organizations (CROs) promote broader adoption of the company's products, integrating them into core service offerings and increasing accessibility for researchers.
Potential Negatives
- Forward-looking statements in the press release indicate uncertainty and potential risks related to the market acceptance and adoption of new products, which could negatively impact investor confidence.
- Expansion into new verticals may strain resources or divert focus from existing successful products, potentially hindering overall performance.
- The reliance on strategic alliances with CROs for product adoption may pose a risk if these partnerships do not yield expected results or if competitive offerings arise.
FAQ
What are the new panels announced by Akoya Biosciences?
Akoya announced new ultrahigh-plex neurobiology panels for human and mouse applications, expanding their product offerings in spatial biology.
When will the Human and Mouse Neurobiology Panels be available?
The Human Neurobiology Panel is set to be released at the end of Q1 2025, while the Mouse Neurobiology Panel will launch at the end of Q2 2025.
What issues do the new neurobiology panels address?
These panels address the need for comprehensive spatial insights in neuroscience research, including neurodegenerative diseases and disease modeling.
How do the new panels enhance research in oncology and neurobiology?
The panels provide advanced tools for studying the immune landscape, tumor-immune interactions, and neuroinflammation, driving breakthroughs in multiple research areas.
What is the role of the PhenoCycler®-Fusion in these new offerings?
The PhenoCycler-Fusion platform enables automated and rapid insights generation, optimizing the capabilities of the new high-plex panels developed by Akoya.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKYA Hedge Fund Activity
We have seen 26 institutional investors add shares of $AKYA stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SVB WEALTH LLC removed 515,317 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,401,662
- PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE added 440,000 shares (+125.7%) to their portfolio in Q3 2024, for an estimated $1,196,800
- POLAR CAPITAL HOLDINGS PLC removed 329,756 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $896,936
- GSA CAPITAL PARTNERS LLP added 144,903 shares (+87.4%) to their portfolio in Q3 2024, for an estimated $394,136
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 112,886 shares (-64.2%) from their portfolio in Q3 2024, for an estimated $307,049
- BLACKROCK, INC. added 78,277 shares (+5.2%) to their portfolio in Q3 2024, for an estimated $212,913
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 74,000 shares (-41.2%) from their portfolio in Q3 2024, for an estimated $201,280
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels
The new offerings solidify leadership in spatial biology and broaden reach to new verticals
MARLBOROUGH, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, a spatial proteomics leader, announced its reagent product roadmap today, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human IO60 and Mouse FFPE IO panels , which debuted at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024, this roadmap represents the next step in the company’s mission to provide cutting-edge tools for advancing research across multiple market including oncology, inflammatory disease and neurobiology.
Transforming Spatial Proteomics with IO60
Since its launch, the PhenoCode™ Discovery IO60 panel has been celebrated by key opinion leaders (KOLs) and contract research organizations (CROs) for its ability to generate deep insights into immune landscapes and tumor-immune interactions. Early adopters have highlighted its transformative potential:
- Dr. Simon Knott, Assistant Professor at Cedars-Sinai, stated, “The IO60 Panel has the potential to reshape spatial proteomics, opening new possibilities for immune research.”
- Dr. Suzuki Yutaka, Professor at the University of Tokyo, added, “With the IO60 Panel, we’re uncovering patterns in immune responses that were previously inaccessible, positioning it as a game-changer for understanding tumor-immune interactions at a deeper level.”
-
Strategic alliances with leading CROs—including
Precision for Medicine
,
BostonGene
, and
Infinity Scope
—have further propelled the adoption of IO60 by integrating it into their core service offerings, making advanced spatial proteomics accessible to all researchers.
Ultrahigh-Plex Neurobiology Panels: A Major Step Forward
Expanding on the success of IO60, the company is set to release PhenoCode Human and Mouse FFPE Neurobiology panels at the end of Q1 and Q2 2025 respectively. These panels will address the critical need for comprehensive spatial insights in neuroscience research, enabling advancements in understanding neurodegenerative diseases, disease modeling, and therapeutic development.
Key Features of the New Human and Mouse Neurobiology Panels:
- Human Neurobiology Panel: This high-plex spatial proteomics panel features an extensive set of biomarkers to study neurodegenerative diseases, neuroinflammation, vascular integrity, and key therapeutic targets, making it a vital tool for advancing neuroscience research.
- Mouse Neurobiology Panel: Specifically optimized for preclinical studies, this panel offers unparalleled biomarker depth to support disease modeling, neurodevelopmental research, and translational applications, bridging the gap between discovery and clinical insights.
-
Seamless Integration with PhenoCycler
®
-Fusion:
Fully automated and optimized for the PhenoCycler-Fusion platform, the fastest spatial proteomics discovery tool, enabling unprecedented speed and resolution in insight generation.
“The rapid expansion of our PhenoCycler-Fusion content menu is a by-product of the efficiency and robustness of our fully operational Manufacturing Center of Excellence,” said Brian McKelligon, CEO of Akoya Biosciences. “Our new ready-to-use high-plex panels in oncology and neurobiology enable us to capture a continuously expanding market segment and drive discoveries and breakthroughs from discovery to translational research.”
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning our expectations about the potential and capabilities of our products, our ability to achieve market acceptance, and drive adoption of, our products, our ability to expand relevant market segments, our projections regarding timing of our future product launches, and other statements regarding our business operations and future performance.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company ® , Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler ® , PhenoImager ® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com .